BioNTech stärkt globale Präsenz durch Übernahme einer GMP-Produktionsanlage zur Errichtung der ersten mRNA-Produktionsstätte in Singapur
November 13, 2022 20:30 ET
|
BioNTech SE
Erste mRNA-Produktionsstätte in Singapur wird regionale Produktionskapazitäten im klinischen und kommerziellen Maßstab schaffen und so BioNTechs wachsende Pipeline mRNA-basierter Impfstoffe und...
BioNTech Expands Global Footprint by Acquiring GMP Manufacturing Site to Establish First mRNA Facility in Singapore
November 13, 2022 20:30 ET
|
BioNTech SE
First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific...
BioNTech und australischer Bundesstaat Victoria schließen strategische Partnerschaft zum Aufbau eines mRNA-Forschungszentrums und einer Produktionsstätte
October 06, 2022 19:30 ET
|
BioNTech SE
BioNTech und der australische Bundesstaat Victoria werden ein mRNA-Forschungs- und Innovationszentrum für innovative Medikamente aufbauen, um translationale Forschung von der frühen Entwicklung bis...
BioNTech and Australia’s State of Victoria Form Strategic Partnership to Establish mRNA Research Center and Manufacturing Facility
October 06, 2022 19:30 ET
|
BioNTech SE
BioNTech and Australia’s State of Victoria will establish an mRNA research and innovation center to strengthen translational research for innovative medicines from discovery to delivery As part of the...
BioNTech und Crescendo Biologics geben globale Kollaboration zur Entwicklung multispezifischer Präzisionsimmuntherapien bekannt
January 10, 2022 08:00 ET
|
BioNTech SE
Die Zusammenarbeit kombiniert BioNTechs unternehmenseigene multimodulare Immuntherapie-Expertise mit Crescendos proprietärer Humabody® VH Plattform zur Entwicklung von Präzisionsimmuntherapien,...
BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies
January 10, 2022 08:00 ET
|
BioNTech SE
Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based...
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development
August 03, 2021 01:00 ET
|
Translate Bio, Inc.
-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi’s recently announced mRNA Center...
28.51% CAGR , mRNA Vaccines & Therapeutics Market Size, Share, significant growth Rate, Trends 2026 by Brandessence Market Research
December 15, 2020 07:39 ET
|
Brandessence Market Research and Consulting Private Limited
Pune, India, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The global demand for mRNA vaccines & therapeutics market size, in terms of revenue, was worth of USD 587.7 million in 2019 and is expected to...
Translate Bio Highlights mRNA Platform Potential for the Treatment of Cystic Fibrosis (CF) at the 34th Annual North American Cystic Fibrosis Conference
October 07, 2020 16:05 ET
|
Translate Bio, Inc.
-- Lead candidate MRT5005 leverages Translate Bio’s proprietary LNP and mRNA platform and is the only clinical-stage mRNA therapeutic in development for the treatment of CF -- -- Second CF program,...
Translate Bio to Participate in Upcoming Investor Conferences
September 29, 2020 16:05 ET
|
Translate Bio, Inc.
LEXINGTON, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...